Literature DB >> 30639308

Tumor recognition of peanut agglutinin-immobilized fluorescent nanospheres in biopsied human tissues.

Hironori Kumagai1, Kosuke Yamada2, Kanako Nakai2, Tokio Kitamura2, Kohta Mohri2, Masami Ukawa2, Takumi Tomono2, Takaaki Eguchi3, Testuya Yoshizaki3, Takumi Fukuchi3, Takuya Yoshino4, Minoru Matsuura5, Etsuo Tobita6, Wellington Pham7, Hiroshi Nakase8, Shinji Sakuma9.   

Abstract

We are investigating an imaging agent for early detection of colorectal cancer. The agent, named the nanobeacon, is coumarin 6-encapsulated polystyrene nanospheres whose surfaces are covered with poly(N-vinylacetamide) and peanut agglutinin that reduces non-specific interactions with the normal mucosa and exhibits high affinity for terminal sugars of the Thomsen-Friedenreich antigen, which is expressed cancer-specifically on the mucosa, respectively. We expect that cancer can be diagnosed by detecting illumination of intracolonically administered nanobeacon on the mucosal surface. In the present study, biopsied human tissues were used to evaluate the potential use of the nanobeacon in the clinic. Prior to the clinical study, diagnostic capabilities of the nanobeacon for detection of colorectal cancer were validated using 20 production batches whose characteristics were fine-tuned chemically for the purpose. Ex vivo imaging studies on 66 normal and 69 cancer tissues removed from the colons of normal and orthotopic mouse models of human colorectal cancer, respectively, demonstrated that the nanobeacon detected colorectal cancer with excellent capabilities whose rates of true and false positives were 91% and 5%, respectively. In the clinical study, normal and tumor tissues on the large intestinal mucosa were biopsied endoscopically from 11 patients with colorectal tumors. Histological evaluation revealed that 9 patients suffered from cancer and the rest had adenoma. Mean fluorescence intensities of tumor tissues treated with the nanobeacon were significantly higher than those of the corresponding normal tissues. Correlation of magnitude relation of the intensity in individuals was observed in cancer patients with a high probability (89%); however, the probability reduced to 50% in adenoma patients. There was a reasonable likelihood for diagnosis of colorectal cancer by the nanobeacon applied to the mucosa of the large intestine.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker imaging; Colorectal cancer; Diagnostic agent; Nanosphere; Optical imaging; Peanut agglutinin; Thomsen-Friedenreich antigen

Mesh:

Substances:

Year:  2019        PMID: 30639308      PMCID: PMC6456895          DOI: 10.1016/j.ejpb.2019.01.007

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  35 in total

1.  Colorectal cancer in inflammatory bowel disease: a continuing problem.

Authors:  R Mayer; W D Wong; D A Rothenberger; S M Goldberg; R D Madoff
Journal:  Dis Colon Rectum       Date:  1999-03       Impact factor: 4.585

2.  Appearance of enhanced tissue features in narrow-band endoscopic imaging.

Authors:  Kazuhiro Gono; Takashi Obi; Masahiro Yamaguchi; Nagaaki Ohyama; Hirohisa Machida; Yasushi Sano; Shigeaki Yoshida; Yasuo Hamamoto; Takao Endo
Journal:  J Biomed Opt       Date:  2004 May-Jun       Impact factor: 3.170

Review 3.  Lewis x is highly expressed in normal tissues: a comparative immunohistochemical study and literature revision.

Authors:  María V Croce; Marina Isla-Larrain; Martín E Rabassa; Sandra Demichelis; Andrea G Colussi; Marina Crespo; Ezequiel Lacunza; Amada Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2007-07-03       Impact factor: 3.201

Review 4.  Pathways of O-glycan biosynthesis in cancer cells.

Authors:  I Brockhausen
Journal:  Biochim Biophys Acta       Date:  1999-12-06

5.  Histological assessment of colorectal adenomas by size. Are polyps less than 10 mm in size clinically important?

Authors:  A J Aldridge; J N Simson
Journal:  Eur J Surg       Date:  2001-10

6.  Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer.

Authors:  S Kudo; H Kashida; T Tamura; E Kogure; Y Imai; H Yamano; A R Hart
Journal:  World J Surg       Date:  2000-09       Impact factor: 3.352

7.  Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study.

Authors:  Sean K Lau; Lawrence M Weiss; Peiguo G Chu
Journal:  Am J Clin Pathol       Date:  2004-07       Impact factor: 2.493

Review 8.  Mucins and mucin binding proteins in colorectal cancer.

Authors:  James C Byrd; Robert S Bresalier
Journal:  Cancer Metastasis Rev       Date:  2004 Jan-Jun       Impact factor: 9.264

9.  Poly(N-vinylacetamide) chains enhance lectin-induced biorecognition through the reduction of nonspecific interactions with nontargets.

Authors:  Ken-ichiro Hiwatari; Shinji Sakuma; Kiyoko Iwata; Yoshie Masaoka; Makoto Kataoka; Hiroyuki Tachikawa; Yoshikazu Shoji; Shinji Yamashita
Journal:  Eur J Pharm Biopharm       Date:  2008-06-05       Impact factor: 5.571

Review 10.  Lectin reactivities as intermediate biomarkers in premalignant colorectal epithelium.

Authors:  C R Boland; M A Martin; I J Goldstein
Journal:  J Cell Biochem Suppl       Date:  1992
View more
  1 in total

1.  PNA-Modified Liposomes Improve the Delivery Efficacy of CAPIRI for the Synergistic Treatment of Colorectal Cancer.

Authors:  Wenbin Diao; Ben Yang; Sipeng Sun; Anping Wang; Rongguan Kou; Qianyun Ge; Mengqi Shi; Bo Lian; Tongyi Sun; Jingliang Wu; Jingkun Bai; Meihua Qu; Yubing Wang; Wenjing Yu; Zhiqin Gao
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.